Campbell Duncan J, Coller Jennifer M, Gong Fei Fei, McGrady Michele, Prior David L, Boffa Umberto, Shiel Louise, Liew Danny, Wolfe Rory, Owen Alice J, Krum Henry, Reid Christopher M
Department of Molecular Cardiology, St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
Intern Med J. 2018 Jun;48(6):688-698. doi: 10.1111/imj.13678.
Effective management of cardiovascular and chronic kidney disease risk factors offers longer, healthier lives and savings in healthcare.
To examine risk factor management in participants of the SCReening Evaluation of the Evolution of New Heart Failure study, a self-selected population at increased cardiovascular disease risk recruited from members of a health insurance fund in Melbourne and Shepparton, Australia.
Inclusion criteria were age ≥ 60 years with one or more self-reported ischaemic or other heart diseases, irregular or rapid heart rhythm, cerebrovascular disease, renal impairment or treatment for hypertension or diabetes for ≥2 years. Exclusion criteria were known heart failure or cardiac abnormality on echocardiography or other imaging. Medical history, clinical examination, full blood examination and biochemistry (without lipids and glycated haemoglobin (HbA1c)) were performed for 3847 participants on enrolment, and blood pressure, lipids and HbA1c were measured 1-2 years after enrolment for 3203 participants.
Despite 99% of 3294 participants with hypertension receiving antihypertensive medication, half had blood pressures >140/90 mmHg. Approximately 77% of participants were overweight or obese, with one third being obese. Additionally, 74% of participants at high cardiovascular disease risk had low-density lipoprotein cholesterol levels ≥2 mmol/L, one third of diabetic participants had HbA1c >7%, 22% had an estimated glomerular filtration rate < 60 mL/min/1.73m , and substantial proportions had under-utilisation of antiplatelet therapy and anticoagulation for atrial fibrillation and were physically inactive.
This population demonstrated substantial potential to reduce cardiovascular and renal morbidity and mortality and healthcare costs through more effective management of modifiable risk factors.
有效管理心血管疾病和慢性肾病风险因素可使人寿命更长、生活更健康,并节省医疗保健费用。
在“新心力衰竭演变筛查评估”研究的参与者中检查风险因素管理情况,该研究的参与者是从澳大利亚墨尔本和谢珀顿的一家健康保险基金成员中招募的心血管疾病风险增加的自我选择人群。
纳入标准为年龄≥60岁,有一项或多项自我报告的缺血性或其他心脏病、心律不齐或快速心律、脑血管疾病、肾功能损害或高血压或糖尿病治疗≥2年。排除标准为已知心力衰竭或超声心动图或其他影像学检查显示心脏异常。对3847名参与者在入组时进行病史、临床检查、全血检查和生化检查(不包括血脂和糖化血红蛋白(HbA1c)),对3203名参与者在入组1 - 2年后测量血压、血脂和HbA1c。
尽管3294名高血压参与者中有99%接受了抗高血压药物治疗,但仍有一半人的血压>140/9 mmHg。约77%的参与者超重或肥胖,其中三分之一为肥胖。此外,74%心血管疾病高风险参与者的低密度脂蛋白胆固醇水平≥2 mmol/L,三分之一的糖尿病参与者HbA1c>7%,22%的参与者估计肾小球滤过率<60 mL/min/1.73m²,并且很大一部分人抗血小板治疗和房颤抗凝治疗使用不足,身体活动不足。
通过更有效地管理可改变的风险因素,该人群在降低心血管和肾脏发病率、死亡率以及医疗保健成本方面具有巨大潜力。